Completed PHASE4 INTERVENTIONAL 2-arm NCT00139152

Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair

Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair

Sponsor: Creighton University

Updated 6 times since 2017 Last updated: Jan 6, 2014 Started: Sep 30, 2005 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Lung Disease and is currently completed. Creighton University leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Feb 2017 — Jun 2018 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Creighton University
Novartis Pharmaceuticals

Data source: Creighton University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Albany, United States
• Omaha, United States